These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37344751)

  • 21. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
    Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
    J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive evaluation in clinic and physiologically-based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450-mediated drug-drug interaction potential for pomotrelvir.
    Yang Z; Rioux N; Vincent L; Jones HM; Cha D; Plummer A; Wilfret D; Kearney BP
    CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1553-1564. PubMed ID: 37614073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates.
    Umehara KI; Huth F; Won CS; Heimbach T; He H
    Biopharm Drug Dispos; 2018 Mar; 39(3):152-163. PubMed ID: 29451681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
    Rytkönen J; Ranta VP; Kokki M; Kokki H; Hautajärvi H; Rinne V; Heikkinen AT
    Biopharm Drug Dispos; 2020 Feb; 41(1-2):72-88. PubMed ID: 31925778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
    Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
    Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
    Konishi K; Minematsu T; Nagasaka Y; Tabata K
    Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.
    Barth A; Perry CR; Shabbir S; Zamek-Gliszczynski MJ; Thomas S; Dumont EF; Brimhall DB; Nguyen D; Srinivasan M; Swift B
    Clin Transl Sci; 2023 Apr; 16(4):647-661. PubMed ID: 36642822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs.
    Darwish M; Youakim JM; Darling I; Lukacova V; Owen JS; Bradley H
    Clin Ther; 2024 Mar; 46(3):194-200. PubMed ID: 38307724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human Pharmacokinetic and CYP3A Drug-Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment.
    Yu J; Tang F; Ma F; Wong S; Wang J; Ly J; Chen L; Mao J
    Drug Metab Dispos; 2024 Jul; 52(8):765-774. PubMed ID: 38811156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
    Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
    J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.
    Li T; Zhou S; Wang L; Zhao T; Wang J; Shao F
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):367-384. PubMed ID: 38554227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
    Schaller S; Martins FS; Balazki P; Böhm S; Baumgart J; Hilger RA; Beelen DW; Hemmelmann C; Ring A
    Br J Clin Pharmacol; 2022 Feb; 88(4):1722-1734. PubMed ID: 34519068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
    Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
    Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
    Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
    J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.